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Abstract
BACKGROUND: Mesoporous nanoparticles have a great potential in targeted therapy approaches due to their ideal properties 
for encapsulation of various drugs, proteins and also biologically active molecules. 
MATERIAL AND METHODS: We used mesoporous hydroxyapatite (HA) nanoparticles as a drug carrier and developed ra-
diolabeled mesoporous HA containing of 2-deoxy-D-glucose (2DG) and Doxorubicin (DOX) with technetium-99m (99mTc) for 
imaging in in vitro and in vivo studies. 
RESULTS: 2DG and DOX in presence of mesoporous HA nanoparticles more reduced the fraction of viable cells in the 
MDA-MB-231, MCF-7 human and MC4-L2 Balb/c mice breast cancer cells. The radiochemical purity of the nano-2DG-DOX 
complex with 99mTc was calculated to 96.8%. The results of cellular uptake showed a 44.77% increase in uptake of the [99mTc]- 
-nano-2DG-DOX compared to the complex without nanoparticles (p < 0.001). 
CONCLUSIONS: Radioisotopic imaging demonstrated a high biochemical stability for [99mTc]-nano-2DG-DOX complex. The 
results demonstrated that [99mTc]-nano-2DG-DOX, may be used as an attractive candidate in cancer imaging and treatment 
managing.
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Introduction
In the past decades, tremendous efforts have been devoted 
to design and functionalize a wide variety of chemical nanoplat-
forms such as liposomes, polymeric micelles, and also magnetic, 
gold and carbon nanostructures. The nanopharmaceutical systems, 
as tumor-targeting carriers, were studied in selective antineoplas-
tic drug delivery and noninvasive imaging of tumors by imaging 
techniques [1–4]. Mesoporous nanoparticles have attracted much 
attention due to their tailorable structures, high specific surface 
areas, large pore volumes and proper encapsulation of drugs, 
proteins and other biologically active molecules [1, 2].
Hydroxyapatite (HA) is another category of nanoplatforms, 
which seems promising for effective delivery system of drugs and 
biological molecules. Some characteristics of this nanoparticle such 
as biocompatibility, bioactivity, diverse morphologies, non-toxicity 
and loss of mutagenicity has made it one of the most efficient 
systems suitable as a drug carrier [2, 3, 5]. Delivery of chemothera-
peutics to cancer cells with the goal of reducing toxic effects on 
healthy tissues is of critical importance. Although, development 
and optimization of various strategies for improvement of this new 
delivery approach is a major challenge for future cancer targeted 
imaging and therapy [1, 4, 6–9]. Various targeting ligands have 
been conjugated to HA nanoparticles, which have shown proper 
tumor cell targeting and enhanced therapeutic efficacy in vitro. 
Mesoporous HA has many advantages over other drug delivery 
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systems including high drug loading capacity, controllable drug 
release system and co-delivery of two or more drugs and also 
therapeutic modalities in combination therapy [2, 10].
Combination of chemotherapeutics is a particularly encourag-
ing approach for optimizing cancer therapy. The combination of 
2-deoxy-D-glucose (2DG), structural analogue of glucose, and 
doxorubicin (DOX), a commonly used anticancer chemodrug, 
have shown a significant cell toxicity on cells with a rapid dividing 
capacity (T47D) compared to 2DG or DOX alone [11–13]. Also it 
was found that 2DG and DOX loaded with mesoporous HA could 
enhance the susceptibility of breast cancer cells to chemotherapy 
and radiotherapy [2, 10].
Recent researches on nuclear medicine imaging have focused 
on development of novel radiopharmaceuticals with improved 
properties to provide a better imaging results in a variety of 
diseases including cancer. Molecular imaging is a non-invasive 
procedure for functional medical imaging in the detection, diag-
nosis and monitoring response to therapy at cellular level in the 
living subjects [14–16]. PET and SPECT imaging techniques have 
been proven to be useful in detecting of malignancies in the initial 
stages [17]. 99mTc is the most frequently used radioisotope regarding 
to its ideal physical (T1/2 = 6 hours, gamma energy 140 keV) and 
chemical properties. This radioisotope represents as an attractive 
candidate for labeling a wide variety of chemical structures including 
nanoparticles [4, 18, 19].
Here, the nano-2DG-DOX complex was labeled with 99mTc for 
an uptake study of breast cancer cells.
Materials and methods
General
The working solutions of 2DG and DOX (purchased from 
Sigma-Aldrich Co., UK and Sobhan Chemotherapeutics Co., 
Iran, respectively) were prepared by dissolving 1M DOX in PBS 
to a final concentration of 1 μM and 2DG to 0.5 mM. 2DG and 
DOX were loaded with 10 mg/mL of mesoporous HA with as, 
BET = 141 (m2g-1), rp,peak (Area) = 4.03 (nm) and total pore vol-
ume (P/P0) = 0.5001 (cm3g-1) in room temperature. An optimum 
concentration of 200 ppm and 5 ppm for 2DG and DOX was found 
as a suitable loading and releasing profile with mesoporous HA, 
respectively [2, 3, 20]. MDA-MB-231 cell line was purchased from 
National Cell Bank of Iran (Pasteur Institute, Iran) and MCF-7 and 
MC4-L2 cell lines were provided from Iranian Biological Resource 
Center (IBRC, Iran). The animals were also purchased from the 
Pasteur Institute, Iran.
Radiolabeling with 99mTc
The labeling process was done in the three repetitions by 
addition of 200 μg SnCl2 (2H2O) to 2 mL of 2DG/DOX loaded 
mesoporous HA as reducing agent, and then adding 1ml of gen-
erator-eluted 99mTcO4
- (aqueous pertechnetate solution, 1000 MBq 
activity) and incubating at room temperature for 60 minutes. The 
resulting 99mTc-complex was filtered through a 0.2-μm pore syringe 
filter. Radiochemical purity was examined by R-TLC [21], using 
Whatman filter paper grade 3 as the stationary phase, acetone and 
0.9% saline solution as the mobile phase [5]. The strips of the filter 
were cut after elution in appropriate time and counted with a gamma 
counter (Leybold, Germany). The stability of [99mTc]-nano-2DG-DOX 
was also assayed three times with the R-TLC method following 
incubation at room temperature for 1, 4 and 24 hours.
Cell culture and treatment
MCF-7 adenocarcinoma (ER+), MB-MDA-231 carcinoma 
(ER-) [22, 23] and MC4-L2 (ER+) breast cancer cells were used 
in this study [24]. The cell lines were cultured in RPMI-1640 media 
supplemented with 10% heat-inactivated (50°C, 30 minutes) fetal 
bovine serum (FBS), penicillin (100 U/mL), streptomycin (100 
μg/mL), and amphotericin B (0.25 μg/mL) at 5% CO2 and 95% air 
in a humidified 37°C incubator [11].
MTT cell viability assay
MB-MDA-231 (7×103 cells/well), MCF-7 (10×103 cells/well) 
and MC4-L2 (8×103 cell/well) cell lines were incubated in 96-well 
plates each containing 200 μL of the supplemented cell culture 
media for 24 hours at 37°C and 5% CO2. The cells were divided in 
8 groups in triplicates: blank, DOX, 2DG, 2DG/DOX, all in presence 
and absence of the nanoparticles, and also nanoparticle alone, all 
in triplicates. The rate of cellular proliferation was measured follow-
ing 24 hours treatment with MTT assay. Briefly, 50 μL of 2 mg/mL 
MTT (3-(4, 5-dimetylthiazol-2-yl)-2, 5-diphenyltrazolium bromide) 
(Roche Diagnostics GmbH, Mannheim, Germany) was added 
to each well. The cells were incubated at 37°C and 5% CO2 for 
4 hours and then the media was discarded and 200 μL of dimethyl 
sulfoxide (DMSO) was added to each well to solubilize the colored 
Formazan product and then 25 μL Sorenson’s buffer was added to 
each well as solubilizer buffer. Finally, the absorbance was read us-
ing an ELISA plate reader (Biotech, Bad Friedrichshall, Germany) at 
570 nm wavelength. All the calculated data were analyzed relatively 
to the untreated cells and then normalized [11].
Cellular uptake assay
For an uptake study, MCF-7, MDA-MB-231 and MC4-L2 
cells were seeded in 12-well plates containing 80,000 cells per 
well. The plates grouped in control and treated including; 99mTc, 
[99mTc]-nanoparticle, [99mTc]-2DG-DOX and [99mTc]-nano-2DG-DOX, 
respectively. The activity was 0.037 MBq in the treatments. After 
incubation for 4 hours (due to T1/2 = 6 hours 99mTc) at 37°C, the 
cells were washed with phosphate-buffered saline (PBS) three 
times and then trypsinized to form the cell suspensions. The sus-
pension was placed in the gamma counter and the uptake of the 
cells was determined [21, 25]. 
99mTc-2DG/DOX Imaging
All invasive procedures were done while the animals were under 
anesthesia (1 ml/kg i.m. of a solution containing 13 mg of Ketamine 
and 86 mg of Xylazine per mL).
The aim of in vivo study was to trace differential uptaking of the 
[99mTc]-nano-2DG-DOX also 99mTc after intravenous injections by car-
rying out a scintigraphic imaging in normal Balb/c mice weighting 
20–30 grams. The dorsal and ventral images were obtained with 
a triple head digital SPECT gamma camera (IRIX Marconi; Philips, 
USA) equipped with LEHR collimators (Matirx: 128 × 128, Mag: 
3.2, Pixel Size: 1.46 mm and Time: 5 minutes). The images were 
acquired two hours after injection of 0.2 mL of the radiolabeled 
complex (3.7 MBq of [99mTc]-nano-2DG-DOX) and also 0.2 mL 99mTc 
(3.7 MBq) alone through the tail vein of the animals.
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killing effects in MDA-MB-231 cells (65.2 ± 6.56%) com-
pared to 2DG alone (81.5 ± 2.89%) (p < 0.001), and MC4-L2 
cells (50.2 ± 1.04%) compared to 2DG (85.7 ± 4.06%) or DOX 
(71.8 ± 1.75%) alone (p < 0.001) than in the control whereas no 
significant difference in MCF-7 cells (p > 0.05). Incubation of the 
cells with the nano drugs for 24 hours reduced the fraction of viable 
cells compared to the drugs alone (p < 0.001).
The differences in viability of the treatments labeled with 99mTc 
were not significant compared to the unlabeled [MDA-MB-231 
(p = 0.893), MCF-7 (p = 0.870) and MC4-L2 (p = 0.963)].
Results on cellular uptake
Uptake of [99mTc]-nano-2DG-DOX, in MDA-MB-231, MCF-7 and 
MC4-L2 breast cancer cells was significantly increased compared 
to the [99mTc]-2DG-DOX and 99mTc (with and without nanoparticle) 
groups when analyzed 4 h after the treatments (Fig. 3) (p < 0.001).
[99mTc]-nano-2DG/DOX Imaging
Radioisotopic images of the normal Balb/c mice with [99mTc]- 
-nano-2DG-DOX and 99mTc alone were presented in Figures 4 and 5.
Discussion
In this study, a complex of mesoporous HA nanoparticle 
with 2DG and DOX was prepared and labeled with 99mTc. The 
radiochemical purity and also stability assays of the labeled nano 
complex were performed by R-TLC method at room temperature 
in 1, 4 and 24 hours intervals and the highest purity and also 
stability was found for 1 hour labelling. The treatment reduced 
Statistical analysis
All the data were expressed as means ± standard error of the 
mean (SEM). One-way analysis of variance (ANOVA) was used to 
compare differences among the treated groups. A Student’s t-test 
was performed for comparisons of the treated groups also with and 
without nanoparticles. Data analysis was performed using Statistical 
Package for the Social Sciences (SPSS) software version 16.0 for 
Windows (SPSS Inc., Chicago, Illinois, USA). A probability value of 
less than 0.05 was considered statistically significant.
Results
Results on 99mTc labeling of nano complex 2DG/DOX
Results of R-TLC showed a high efficiency of the nano-2DG-DOX 
complex labeling, with the mean percentage of 93.367 ± 3.61% 
for all the labeling times with the highest percentage up to 96.8% 
(Fig. 1) for 1 hour (p = 0.09). The stability of the complex reached 
to 96.1% when 99mTcO4
– was added to nano-2DG-DOX at room 
temperature after 1 hour (Fig. 2). The percentage of stability of the 
nano complex was obtained 90.467 ± 5.06 for the assay times of 
1, 4 and 24 hours (all p < 0.001).
Results on cytotoxic effects of the treatments on 
MDA-MB-231, MCF-7 and Mc4-L2 breast cancer cell 
lines
The results of cell viability analysis in the three types of treats in 
presence and absence of nanoparticle on the cell lines have been 
summarized in Table 1. Treatment of the cells for 24 hours with 
a combination of 2DG and DOX have shown a significant cell 
Figure 1. Labeling yields of [99mTc]-nano-2DG-DOX assayed by R-TLC 
method
Figure 2. Stability of [99mTc]-nano-2DG-DOX assayed by R-TLC 
method
Table 1. The results on viability of MDA-MB-231, MCF-7 and MC4-L2 cells following treatment with mesoporous HA nanoparticles with and without 
DOX and 2DG. The cells were cultivated for 24 hours under the standard growth conditions
Cell Line Cell Viability [%]
2DGa DOXb 2DG + DOX Npc 2DG+NP DOX+NP 2DG+DOX+NP
MDA-MB-231 81.5 ± 2.89 67.7 ± 2.66 65.2 ± 6.56 91.4 ± 3.94 49.1 ± 2.27 48 ± 2.76 39.8 ± 2.89
MCF-7 92.2 ± 1.89 77.5 ± 2.5 88.5 ± 7.94 93.6 ± 1.89 52.4 ± 1.73 54.4 ± 10.99 66.1 ± 8.31
MC4-L2 85.7 ± 4.06 71.8 ± 1.75 50.2 ± 1.04 98.5 ± 3.6 59.5 ± 1.87 52.6 ± 1.27 55.4 ± 3.08
a2DG — 2-deoxy-D-Glucose; bDOX — Doxorubicin; cNP — Nano Particle
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viability in the cells was significant compared to the untreated con-
trols (p < 0.001). Also the cellular uptake of [99mTc]-nano-2DG-DOX 
was calculated to 65.8%, 55.7% and 68.7% in the three cell lines, 
respectively, at room temperature 4 h after the treatment in vitro. In 
radioisotopic imaging studies, the percentages of reduced [99mTc]- 
-nano-2DG-DOX uptake was found 96.56%, 84.57%, and 80.10% 
in salivary glands, stomach and bladder of normal Balb/c mice, 
respectively, compared to 99mTc alone 2 hours after the injection. 
The combination of 2DG and DOX was reduced cellular viability 
to some extent in slowly growing MCF-7 cells, while a significant cell 
killing was induced in rapidly dividing cells including MDA-MB-231 
and MC4-L2 (Table 1). These results confirmed previous studies on 
growth inhibition and cytotoxicity of combined 2DG/BSO and also 
2DG/DOX in MDA-MB-231 [22] and MCF-7 [13] cells. However, 
mesoporous HA nanoparticles alone was shown non-toxic ef-
fects on the three cell lines (Table 1). Meanwhile, mesoporous HA 
nanoparticles containing 2DG or DOX and also in the combination 
decreased the cell viability 24 h after the treatments. The results on 
viability confirmed the previous study on the reducing viability of 
magnetic mesoporous HA coated by SPIONs nanoparticles, con-
taining DOX and 2DG, on T47D and SKBR3 cell lines [2, 10]. The 
Minor differences with our findings may related to the difference 
sensitivity of the studied cell lines.
The [99mTc]-nano-2DG-DOX exhibited an excellent labeling 
efficiency (> 93.37%) (Fig. 1). In addition, the difference on nano 
complex cellular uptake compared with [99mTc]-2DG-DOX, [99mTc]- 
-nanoparticle, and 99mTc alone was obtained 63.4%, 18.6%, 39%, and 
1.15%, respectively (Fig. 3). Therefore, it suggests an increased up-
take capability in human and mice breast cancer cells. The obtained 
results are in agreement with the previous studies on the radiola-
beling, uptaking and also biodistribution of [99mTc]-DTPA-DG [21], 
[99mTc]–2-[(3-carboxy-1-oxopropyl)amino]-2-deoxy-D-glucose [26], 
[99mTc]-DOX loaded nanoparticles [27] and [99mTc]-nano hydro-
xyapatite [5]. Our results on the labelling and cell uptaking of 
[99mTc]-nano-2DG-DOX could confirm the claim that the radiolabeled 
nanoparticle is an attractive candidate in cancer therapy, owing to 
its great potential for radioisotopic imaging study [4, 18, 28, 29].
Furthermore, the radioisotopic imaging study of [99mTc]- 
-nano-2DG-DOX in the normal Balb/c mice was performed to 
ascertain whether the organ uptake of the nano complex was per-
fusion related. The images were also acquired with 99mTc alone in 
the normal mice 2 hours after injection. The difference on [99mTc]- 
-nano-2DG-DOX uptake in thyroid, salivary gland and gastric 
mucosa compared to 99mTc alone (Fig. 4), indicating the related 
suitable bio-stability may provide a differential absorption for further 
tumor study in vivo.
Figure 4. Planar imaging obtained at 2 hours after administration 3.7 
MBq of [99mTc]-2DG/DOX in the normal Balb/c mice. There was no sign 
of radioactivity in thyroid and salivary gland, or gastric mucosa
Figure 5. Planar imaging obtained at 2 hours after administration 3.7 
MBq of 99mTc in the normal Balb/c mice
Figure 3. In vitro cellular uptake of [99mTc]–2DG/DOX and also 99mTc 
with and without nanoparticle in MDA-MB-231, MCF-7 and MC4-L2 
cells
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Conclusions
In this study, we demonstrated the potential of mesoporous HA 
nanoparticles as the drug carrier in enhancing tumor targeted 
delivery of 2DG and DOX in breast cancer cells. The [99mTc]-na-
no-2DG-DOX exhibited an excellent stability and target specificity 
in vitro and also in vivo. There are needed some more studies to 
suggest [99mTc]-nano-2DG-DOX as a candidate in cancer imaging.
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